Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC)

Conditions:   RCC;   Renal Cell Carcinoma Interventions:   Drug: Cabozantinib 80 MG;   Drug: Cabozantinib 40Mg Tab;   Drug: Nivolumab Sponsors:   University of Texas Southwestern Medical Center;   Exelixis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials